KR20190039220A - 국소적 라파마이신 요법 - Google Patents

국소적 라파마이신 요법 Download PDF

Info

Publication number
KR20190039220A
KR20190039220A KR1020197006896A KR20197006896A KR20190039220A KR 20190039220 A KR20190039220 A KR 20190039220A KR 1020197006896 A KR1020197006896 A KR 1020197006896A KR 20197006896 A KR20197006896 A KR 20197006896A KR 20190039220 A KR20190039220 A KR 20190039220A
Authority
KR
South Korea
Prior art keywords
composition
rapamycin
treatment
patient
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197006896A
Other languages
English (en)
Korean (ko)
Inventor
메리 케이 쾨닉
홉 노스럽
애들레이드 에이. 히버트
Original Assignee
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 filed Critical 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
Publication of KR20190039220A publication Critical patent/KR20190039220A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197006896A 2016-08-10 2017-08-10 국소적 라파마이신 요법 Ceased KR20190039220A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662372940P 2016-08-10 2016-08-10
US62/372,940 2016-08-10
PCT/US2017/046320 WO2018031789A1 (en) 2016-08-10 2017-08-10 Topical rapamycin therapy

Publications (1)

Publication Number Publication Date
KR20190039220A true KR20190039220A (ko) 2019-04-10

Family

ID=59684091

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197006896A Ceased KR20190039220A (ko) 2016-08-10 2017-08-10 국소적 라파마이신 요법

Country Status (11)

Country Link
US (1) US20190167649A1 (enExample)
EP (1) EP3496712A1 (enExample)
JP (1) JP2019527711A (enExample)
KR (1) KR20190039220A (enExample)
CN (1) CN109689053A (enExample)
AU (1) AU2017311491A1 (enExample)
BR (1) BR112019002689A2 (enExample)
CA (1) CA3032473A1 (enExample)
MX (1) MX2019001670A (enExample)
RU (1) RU2019106483A (enExample)
WO (1) WO2018031789A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
WO2019156999A1 (en) * 2018-02-06 2019-08-15 Georgetown University TOPICAL mTOR INHIBITORS FOR CUTANEOUS PROLIFERATIVE AND VASCULAR CONDITIONS
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
EP3829578A4 (en) * 2018-08-30 2022-08-17 Chemistryrx COMPOSITIONS CONTAINING SIROLIMUS
CN109431997B (zh) * 2018-12-20 2021-06-04 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法
JP2022521006A (ja) 2019-02-20 2022-04-04 エイアイ・セラピューティクス・インコーポレーテッド 局所ラパマイシン製剤ならびに顔面血管線維腫および他の皮膚疾患の治療におけるそれらの使用
WO2020175131A1 (ja) * 2019-02-27 2020-09-03 国立大学法人大阪大学 脈管異常治療用外用剤
JP7755854B2 (ja) * 2020-01-24 2025-10-17 ノーベルファーマ株式会社 ラパマイシン含有外用剤
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition
AU2023203871B1 (en) * 2023-06-20 2024-07-25 Aft Pharmaceuticals Ltd A Rapamycin Method of Treatment and Composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
AU2003259803B2 (en) 2002-08-12 2007-08-02 The Regents Of The University Of Michigan Diagnosis and treatment of tuberous sclerosis
EP1853612A1 (en) 2005-03-02 2007-11-14 Wyeth Purification of rapamycin
AU2007211613C1 (en) 2006-02-02 2018-01-04 Novartis Ag Tuberous Sclerosis treatment
US20120022095A1 (en) 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
WO2012142145A1 (en) * 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
CA2899206C (en) * 2013-01-24 2019-07-09 Transderm, Inc. Compositions for transdermal delivery of mtor inhibitors
HUP1400075A2 (hu) * 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
KR20180081501A (ko) * 2015-09-24 2018-07-16 드렉셀유니버시티 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途

Also Published As

Publication number Publication date
RU2019106483A (ru) 2020-09-11
WO2018031789A1 (en) 2018-02-15
US20190167649A1 (en) 2019-06-06
JP2019527711A (ja) 2019-10-03
CA3032473A1 (en) 2018-02-15
MX2019001670A (es) 2019-07-04
CN109689053A (zh) 2019-04-26
BR112019002689A2 (pt) 2019-05-14
EP3496712A1 (en) 2019-06-19
RU2019106483A3 (enExample) 2020-12-04
AU2017311491A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
KR20190039220A (ko) 국소적 라파마이신 요법
AU2014287408B2 (en) Treatment of inflammatory lesions of rosacea with ivermectin
US8354424B2 (en) Method of treating actinic keratosis
KR20140004186A (ko) 표면활성제 조성물
IL269182B1 (en) Methods for the treatment and/or prevention of actinic radiation
Stein et al. Betamethasone valerate foam for treatment of nonscalp psoriasis
TWI863995B (zh) 皮膚型紅斑狼瘡之治療
JP6929860B2 (ja) 手湿疹の治療
US20050089485A1 (en) Sulfacetamide formulations for treatment of rosacea
JP5513705B2 (ja) 知覚過敏型肌掻痒感改善剤
CA3131366A1 (en) External preparation for vascular abnormality treatment
US20230270714A1 (en) Salvinorin compositions
CA2565213C (en) Use of 7-t-butoxyiminomethylcamptothecin for the preparation of a medicament for the treatment of uterine neoplasms
US8501202B2 (en) Sulfacetamide formulations for treatment of skin dermatoses
JP7514598B2 (ja) 皮膚外用組成物
HK40063225A (en) Treatment of cutaneous lupus erythematosus
Prous Annual Update 2003/2004-Treatment of dermatological disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190308

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200806

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211027

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220203

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211027

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I